Смена линейной дифференцировки в рецидиве острого лейкоза с перестройкой гена MLL (KMT2A). Обзор литературы и описание случаев

Смена линейной дифференцировки – редкое явление, при котором в рецидиве острого лейкоза наблюдается переход из лимфоидного фенотипа в миелоидный или наоборот. В настоящей работе представлены описания 4 клинических случаев острого лимфобластного лейкоза с перестройкой гена MLL (KMT2A), в рецидиве заболевания продемонстрировавших миелоидный фенотип.

1. Pui C. H., Mullighan C. G., Evans W. E. et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?, Blood 2012;120(6):1165–74. DOI: 10.1182/ blood-2012‑05‑378943; PMID: 22730540.

2. Hunger S. P., Lu X., Devidas M. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children»s oncology group. J Clin Oncol. 2012;30(14):1663–9. DOI: 10.1200/JCO. 2011.37.8018; PMID: 22412151.

3. Conter V., Arico M., Basso G. et al. Long- term results of the Italian Association of Pediatric Hematology and Oncology(AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010;24(2):255–64. DOI: 10.1038/ leu. 2009.250; PMID: 20016536.

4. Moricke A., Zimmermann M., Reiter A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24(2):265–84. DOI: 10.1038/leu. 2009.257; PMID: 20010625.

5. Sander A., Zimmermann M., Dworzak M. et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010;24(8):1422–8. DOI: 10.1038/ leu. 2010.127; PMID: 20535146.

6. Vora A., Goulden N., Wade R. et al., Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease(UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199–209. DOI: 10.1016/S1470–2045(12) 70600–9; PMID: 23395119.

7. Burnett A. K., Hills R. K., Milligan D. et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77. DOI: 10.1200/ JCO. 2010.31.4310; PMID: 21172891

8. Burnett A. K., Russell N. H., Hills R. K. et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360–8. DOI: 10.1200/JCO. 2012.47.4874; PMID: 23940227.

9. Ribeiro R. C., Razzouk B. I., Pounds S. et al. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children»s Research Hospital, from 1980 to 2000. Leukemia 2005;19(12):2125–9. DOI: 10.1038/ sj. leu. 2403872; PMID: 16281077.

10. Stass S., Mirro J., Melvin S. et al. Lineage switch in acute leukemia. Blood 1984;64(3):701–6. PMID: 6590097.

11. Chung H. J., Park C. J., Jang S. et al. A case of lineage switch from acute lymphoblastic leukemia to acute myeloid leukemia. Korean J Lab Med. 2007;27(2):102–5. DOI: 10.3343/ kjlm. 2007.27.2.102; PMID: 18094559.

12. Dorantes-Acosta E., Pelayo R. Lineage switching in acute leukemias: a consequence of stem cell plasticity?, Bone Marrow Res 2012;2012:406–796. DOI: 10.1155/2012/406796; PMID: 22852088.

13. Paganin M., Buldini B., Germano G. et al. A case of T-cell acute lymphoblastic leukemia relapsed as myeloid acute leukemia. Pediatr Blood Cancer 2016;5(3), [Epub ahead of print]. DOI: 10.1002/pbc. 26054; PMID: 27149388.

14. Э. Г. Бойченко, А. М. Попов, Т. А. Макарова и др. Острый лимфобластный лейкоз из ранних предшественников Т-клеток. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2015;14(1):38–44. [Boychenko E. G., Popov A. M., Makarova T. A. et al. Acute lymphoblastic leukemia from early T-cell precursor. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric hematology/oncology and immunopathology 2015;14(1):38–44 (In Russ.)

15. Rayes A., McMasters R. L., O»Brien M. M. Lineage switch in MLLrearranged infant leukemia following CD19- directed therapy. Pediatr Blood Cancer 2016;63(6):1113–5. DOI: 10.1002/pbc. 25953; PMID: 26914337.

16. Fallah Azad V., Hedayati Asl A. A., Tashvighi M. et al. CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia. Med Mol Morphol. 2016;49(1):53–6. DOI: 10.1007/ s00795‑015‑0117‑0; PMID: 26242204.

17. Hutter C., Attarbaschi A., Fischer S. et al. Acute monocytic leukaemia originating from MLL–MLLT3-positive pre-B cells. Br J Haematol. 2010;150(5):621–3. DOI: 10.1111/j. 1365–2141.2010.08239. x.; PMID: 20497176.

18. Winter S. S., Greene J. M., McConnell T. S. et al. Pre-B acute lymphoblastic leukemia with b3a2(p210) and e1a2(p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2(p210) clone. Leukemia 1999;13(12):2007–11. PMID: 10602422.

19. Oh S. H., Park T. S., Kim H. R. et al. Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia. Leuk Res. 2009:33(11):195–8. DOI: 10.1016/j. leukres. 2009.04.026; PMID: 19446879.

20. Germano G., Pigazzi M., del Giudice L. et al. Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia. Haematologica 2006;91(5):ECR09. PMID: 16709517.

21. Bierings M., Szczepanski T., van Wering E. R. et al. Two consecutive immunophenotypic switches in a child with immunogenotypically stable acute leukaemia. Br J Haematol. 2001;113(3):757–62. DOI: 10.1046/j. 1365–2141.2001.02772. x; PMID: 11380467.

22. Bresters D., Reus A. C., Veerman A. J. et al. Congenital leukaemia: the Dutch experience and review of the literature. Br J Haematol 2002:117(3):513–24. DOI: 10.1046/j. 1365– 2141.2002.03459. x; PMID: 12028017.

23. Fernandez M. C., Weiss B., Atwater S. et al. Congenital leukemia: successful treatment of a newborn with t(5;11)(q31; q23). J Pediatr Hematol Oncol 1999:21(2):152–7. PMID: 10206463.

24. Killick S., Matutes E., Powles R. L. et al. Outcome of biphenotypic acute leukemia. Haematologica 1999;84(8):699–706. PMID: 10457405.

25. Owaidah T. M., Al Beihany A., Iqbal M. A. et al. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia 2006;20(4):620–6. DOI: 10.1038/sj. leu. 2404128; PMID: 16437134.

26. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, ed. S. S. H., et al. 2008, Lyon: IARC.

27. Katsura Y., Kawamoto H. Stepwise lineage restriction of progenitors in lymphomyelopoiesis. Int Rev Immunol. 2001;20(1):1– 20. PMID: 11342295.

28. Katsura Y. Redefinition of lymphoid progenitors. Nat Rev Immunol 2002:2(2): 127– 32. DOI: 10.1038/nri721; PMID: 11910894.

29. Kawamoto H. A close developmental relationship between the lymphoid and myeloid lineages. Trends Immunol 2006:27(4):169–75. DOI: 10.1016/j. it. 2006.02.004; PMID: 16515884

30. Kawamoto H., Katsura Y. A new paradigm for hematopoietic cell lineages: revision of the classical concept of the myeloidlymphoid dichotomy. Trends Immunol 2009;30(5):193–200. DOI: 10.1016/j. it. 2009.03.001; PMID: 19356980.

31. Bell J. J., Bhandoola A. The earliest thymic progenitors for T-cells possess myeloid lineage potential. Nature 2008;452(7188):764–7. DOI: 10.1038/nature06840; PMID: 18401411.

32. Pui C. H., Raimondi S. C., Behm F. G. et al. Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia. Blood 1986;68(6):1306–10. PMID: 2946333.

33. Messina M., Chiaretti S., Iacobucci I. et al. AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. Br J Haematol 2011:152(6):727–32. DOI: 10.1111/j. 1365–2141.2010.08449. x.; PMID: 21623761.

34. Cozzio A., Passegue E., Ayton P. M. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17(24):3029– 35. DOI: 10.1101/gad. 1143403; PMID: 14701873.

35. Eppert K., Takenaka K., Lechman E. R. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17(9):1086–93. DOI: 10.1038/nm. 2415; PMID: 21873988.

36. Gentles A. J., Plevritis S. K., Majeti R. et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010;304(24);2706–15. DOI: 10.1001/jama. 2010.1862; PMID: 21177505.

37. Valk P. J., Verhaak R. G., Beijen M. A. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350(16):1617–28. DOI: 10.1056/ NEJMoa040465; PMID: 15084694.

38. Strauss R., Hamerlik P., Lieber A. et al. Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer. Mol Ther 2012;20(5):887–97. DOI: 10.1038/mt. 2012.2; PMID: 22314288.

39. Wernig M., Meissner A., Foreman R. et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448(7151):318–24. DOI: 10.1038/ nature05944; PMID: 17554336.

40. Ng R. K., Kong C. T., So C. C. et al. Epigenetic dysregulation of leukaemic HOX code in MLL-rearranged leukaemia mouse model. J Pathol 2014;232(1):65–74. DOI: 10.1002/path. 4279; PMID: 24122813.

41. Andersson A. K., Ma J., Wang J. et al. The landscape of somatic mutations in infant MLL- earranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–7. DOI: 10.1038/ng. 3230; PMID: 25730765.

42. Weir E. G., Ali Ansari-Lari M., Batista D. A. et al. Acute bilineal leukemia: a rare disease with poor outcome. Leukemia 2007;21(11):2264–70. DOI: 10.1038/sj. leu. 2404848; PMID: 17611554.

43. Bardini M., Woll P. S., Corral L. et al. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia 2015;29(1):38–50. DOI: 10.1038/leu. 2014.154; PMID: 24798483.

44. Panzer-Grumayer E. R., Cazzaniga G., van der Velden V. H. et al. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin Cancer Res 2005;11(21):7720– 7. DOI: 10.1158/1078–0432. CCR-05-1239;PMID: 16278392